We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ultra-Specific, Non-Invasive Saliva Test Enables Quantitative Testing Of COVID-19 Antibodies

By LabMedica International staff writers
Posted on 09 Dec 2020
A home-collection assay for the quantitative testing of COVID-19 antibodies using saliva now makes it possible for individuals to monitor the level of their COVID-19 antibodies over time without leaving home.

Liquid Diagnostics (San Clemente, CA, USA) has developed and successfully carried out CLIA validation of the test which utilizes the company’s proprietary Amperial technology and measures IgG to the S1 domain of the SARS-CoV-2 spike protein. The Amperial chemistry is based on immobilizing biomolecules in a conducting gel matrix and measuring current following electrochemical detection.

Illustration
Illustration

This quantitative COVID-19 antibody test is the first home-collection, ultra-specific, non-invasive saliva test. The test is perfect for monitoring both epidemiologic and vaccine response studies because of its unparalleled specificity of this assay and because individuals can collect samples with an easy-to-use mouth swab at home and mail the sample to a centralized laboratory. Results can be returned the day following the receipt of the sample. Individuals can be tested multiple times to assess the persistence of COVID-19 antibody production following exposure or vaccination.

A CLIA evaluation showed that the test has a specificity (absence of false negatives) of at least 99.994% and a positive predictive value of > 96% (the percentage of positive tests that are true positives). The test is classified as a Laboratory Developed Test. An emergency use authorization (EUA) application has been filed and is awaiting FDA clearance.

"With increasing evidence that the presence of SARS-CoV-2 antibodies correlates with immunity to infection, our Amperial assay with its exquisite specificity and high positive predictive value could be useful for essential workers to determine if they have already had a COVID-19 infection and developed immunity," said Dr. Charles Strom, CEO of Liquid Diagnostics, LLC. "Because it quantifies the amount of antibodies, the test could be used to track the persistence of antibodies following infection or vaccination to assess the potential need for booster shots."

Related Links:
Liquid Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
09 Dec 2020  |   COVID-19

Long COVID Etiologies Found in Acute Infection Blood Samples
09 Dec 2020  |   COVID-19

Novel Device Detects COVID-19 Antibodies in Five Minutes
09 Dec 2020  |   COVID-19